{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:04:22Z","timestamp":1790003062246,"version":"4.0.1"},"reference-count":47,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AEI (Government of Spain","award":["PID2019-105813RB-C21"],"award-info":[{"award-number":["PID2019-105813RB-C21"]}],"id":[{"id":"https:\/\/ror.org\/038jjxj40","id-type":"ROR","asserted-by":"crossref"}]},{"award":["PID2019-105813RB-C21"],"award-info":[{"award-number":["PID2019-105813RB-C21"]}],"id":[{"id":"https:\/\/ror.org\/038jjxj40","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Herein, we have identified the polyfunctionalized 1-(phenylsulfonyl)-1H-indole-2-carboxylic acid derivative MTP150 for the treatment of neurodegenerative diseases owing to its efficacy in reducing protein aggregation, modulating matrix metalloproteinase activity, mitigating neuroinflammation, and enhancing DNA damage repair pathways across in vivo Caenorhabditis elegans models of Alzheimer\u2019s disease, Parkinson\u2019s disease (PD), and Huntington\u2019s disease. Further experiments in an in vivo Drosophila model of PD showed that MTP150 increased motor performance, reduced oxidative stress levels, and restored mitochondrial function in model flies. In addition, MTP150 exhibited neuroprotective effects in PD model cells, thereby supporting its therapeutic potential for this disease.<\/jats:p>","DOI":"10.3390\/ijms27073135","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:20:47Z","timestamp":1774884047000},"page":"3135","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson\u2019s Disease"],"prefix":"10.3390","volume":"27","author":[{"given":"Mireia","family":"Toledano-Pinedo","sequence":"first","affiliation":[{"name":"Institute of General Organic Chemistry (CSIC), C\/Juan de la Cierva 3, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8310-1549","authenticated-orcid":false,"given":"Alicia","family":"Porro-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Institute of General Organic Chemistry (CSIC), C\/Juan de la Cierva 3, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Sch\u00e4ker-H\u00fcbner","sequence":"additional","affiliation":[{"name":"Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Diez-Iriepa","sequence":"additional","affiliation":[{"name":"Institute of General Organic Chemistry (CSIC), C\/Juan de la Cierva 3, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3475-9624","authenticated-orcid":false,"given":"Isabel","family":"Iriepa","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Org\u00e1nica y Qu\u00edmica Inorg\u00e1nica, Instituto de Investigaci\u00f3n Qu\u00edmica \u201cAndr\u00e9s M. del R\u00edo\u201d (IQAR), Universidad de Alcal\u00e1, 28805 Alcal\u00e1 de Henares, Spain"},{"name":"Grupo DISCOBAC, Instituto de Investigaci\u00f3n Sanitaria de Castilla-La Mancha (IDISCAM), 45071 Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Siwek","sequence":"additional","affiliation":[{"name":"Department of Pharmacobiology, Faculty of Pharmacy, Medical College, Jagiellonian University, 9 Medyczna St., 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Wolak","sequence":"additional","affiliation":[{"name":"Department of Pharmacobiology, Faculty of Pharmacy, Medical College, Jagiellonian University, 9 Medyczna St., 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Sata\u0142a","sequence":"additional","affiliation":[{"name":"Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Sm\u0119tna Street, 31-343 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-6333","authenticated-orcid":false,"given":"Andrzej","family":"Bojarski","sequence":"additional","affiliation":[{"name":"Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Sm\u0119tna Street, 31-343 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Doroz-P\u0142onka","sequence":"additional","affiliation":[{"name":"Department of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, 9 Medyczna Street, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3674-3581","authenticated-orcid":false,"given":"Jadwiga","family":"Handzlik","sequence":"additional","affiliation":[{"name":"Department of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, 9 Medyczna Street, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-2772","authenticated-orcid":false,"given":"Justyna","family":"Gody\u0144","sequence":"additional","affiliation":[{"name":"Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Medical College, Jagiellonian University, 9 Medyczna Street, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-615X","authenticated-orcid":false,"given":"Patrick","family":"Dallemagne","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Caen Normandie, Normandie University, CERMN UR4258, F-14000 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-2082","authenticated-orcid":false,"given":"Christophe","family":"Rochais","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Caen Normandie, Normandie University, CERMN UR4258, F-14000 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0157-2380","authenticated-orcid":false,"given":"Audrey","family":"Davis","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Caen Normandie, Normandie University, CERMN UR4258, Druid Platform, F-14000 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3984-5812","authenticated-orcid":false,"given":"Marc","family":"Since","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Caen Normandie, Normandie University, CERMN UR4258, Druid Platform, F-14000 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-1704","authenticated-orcid":false,"given":"Bel\u00e9n","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Therapeutic and Toxicology, Universitat Aut\u00f2noma de Barcelona, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-753X","authenticated-orcid":false,"given":"Aina","family":"Bellver-Sanchis","sequence":"additional","affiliation":[{"name":"Pharmacology Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Neuroscience, Universitat de Barcelona (NeuroUB), Av. Joan XXIII 27\u201331, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5850-5058","authenticated-orcid":false,"given":"Alba","family":"Irisarri","sequence":"additional","affiliation":[{"name":"Pharmacology Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Neuroscience, Universitat de Barcelona (NeuroUB), Av. Joan XXIII 27\u201331, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3095-4254","authenticated-orcid":false,"given":"Merc\u00e8","family":"Pall\u00e0s","sequence":"additional","affiliation":[{"name":"Pharmacology Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Neuroscience, Universitat de Barcelona (NeuroUB), Av. Joan XXIII 27\u201331, 08028 Barcelona, Spain"},{"name":"Institut de Neuroci\u00e8ncies, Universitat de Barcelona (NeuroUB), 08193 Barcelona, Spain"},{"name":"Spanish Biomedical Research Center in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Solana-Manrique","sequence":"additional","affiliation":[{"name":"Departamento de Gen\u00e9tica, Facultad CC Biol\u00f3gicas, Universidad de Valencia, 46100 Burjassot, Spain"},{"name":"Instituto Universitario de Biotecnolog\u00eda y Biomedicina (BIOTECMED), Universidad de Valencia, 46100 Burjassot, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5188-6038","authenticated-orcid":false,"given":"Francisco","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences\u2013HM Hospitals, Camilo Jos\u00e9 Cela University, 28692 Madrid, Spain"},{"name":"HM Hospitals Health Research Institute, 28015 Madrid, Spain"},{"name":"Neuropsychopharmacology Unit, \u201cHospital 12 de Octubre\u201d Research Institute, 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6013-3150","authenticated-orcid":false,"given":"Lhassane","family":"Ismaili","sequence":"additional","affiliation":[{"name":"Laboratoire de Recherches Int\u00e9gratives en Neurosciences et Psychologie Cognitive de Besan\u00e7on, Groupe Chimie M\u00e9dicinale, Universit\u00e9 de Franche-Comt\u00e9, INSERM, UMR 1322 LINC, F-25000 Besanc\u0327on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5424-9130","authenticated-orcid":false,"given":"Christian","family":"Gri\u00f1\u00e1n-Ferr\u00e9","sequence":"additional","affiliation":[{"name":"Pharmacology Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Neuroscience, Universitat de Barcelona (NeuroUB), Av. Joan XXIII 27\u201331, 08028 Barcelona, Spain"},{"name":"Institut de Neuroci\u00e8ncies, Universitat de Barcelona (NeuroUB), 08193 Barcelona, Spain"},{"name":"Spanish Biomedical Research Center in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7193-2532","authenticated-orcid":false,"given":"Nuria","family":"Paricio","sequence":"additional","affiliation":[{"name":"Departamento de Gen\u00e9tica, Facultad CC Biol\u00f3gicas, Universidad de Valencia, 46100 Burjassot, Spain"},{"name":"Instituto Universitario de Biotecnolog\u00eda y Biomedicina (BIOTECMED), Universidad de Valencia, 46100 Burjassot, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9765-5975","authenticated-orcid":false,"given":"Finn K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2549-170X","authenticated-orcid":false,"given":"Anna","family":"Wi\u0119ckowska","sequence":"additional","affiliation":[{"name":"Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Medical College, Jagiellonian University, 9 Medyczna Street, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Marco-Contelles","sequence":"additional","affiliation":[{"name":"Institute of General Organic Chemistry (CSIC), C\/Juan de la Cierva 3, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Almaghrabi, M. (2025). Multitarget-directed ligands for Alzheimer\u2019s disease: Recent novel MTDLs and mechanistic insights. Pharmaceuticals, 18.","DOI":"10.3390\/ph18111685"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"104457","DOI":"10.1016\/j.drudis.2025.104457","article-title":"Beyond purinergic signaling: Dual ligand approaches to multitarget drug discovery","volume":"30","author":"Francucci","year":"2025","journal-title":"Drug Discov. Today"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16533","DOI":"10.1021\/acs.jmedchem.4c01367","article-title":"Contilisant+Tubastatin A hybrids: Polyfunctionalized indole derivatives as new active HDAC inhibitor-based multitarget small molecules with in vitro and in vivo activity in neurodegenerative diseases","volume":"67","author":"Romero","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/acsptsci.4c00709","article-title":"Contilisant-belinostat hybrids: Polyfunctionalized indole derivatives as multineurotarget drugs for the potential treatment of Alzheimer\u2019s disease","volume":"8","author":"Eimermacher","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","article-title":"Belinostat: First global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1039\/D3MD00621B","article-title":"The allure of targets for novel drugs","volume":"15","author":"Suckling","year":"2024","journal-title":"RSC Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","article-title":"The application of histone deacetylases inhibitors in glioblastoma","volume":"39","author":"Chen","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.2174\/0109298673320300240930064551","article-title":"Computational approaches for multitarget drug design in Alzheimers disease: A comprehensive review","volume":"32","author":"Guerguer","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e202500053","DOI":"10.1002\/cbic.202500053","article-title":"The evolution of AChE inhibitors in Alzheimer\u2032s disease: From single-target to multi-target ligands","volume":"26","author":"Mehta","year":"2025","journal-title":"ChemBioChem"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40120-018-0095-y","article-title":"5HT6 Antagonists in the treatment of Alzheimer\u2019s dementia: Current progress","volume":"7","author":"Andrews","year":"2018","journal-title":"Neurol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40263-016-0399-3","article-title":"Serotonin 5-HT6 receptor antagonists in Alzheimer\u2019s disease: Therapeutic rationale and current development status","volume":"31","author":"Ferrero","year":"2017","journal-title":"CNS Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1474-4422(14)70198-X","article-title":"Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer\u2019s disease (LADDER): A randomised, double-blind, placebo-controlled phase 2 trial","volume":"13","author":"Wilkinson","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1734-1140(10)70315-7","article-title":"Potential role of the 5-HT6 receptor in depression and anxiety: An overview of preclinical data","volume":"62","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0165-0173(02)00268-0","article-title":"Neurotransmitter systems involved in learning and memory in the rat: A meta-analysis based on studies of four behavioral tasks","volume":"41","author":"Myhrer","year":"2003","journal-title":"Brain Res. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0893-133X(01)00265-2","article-title":"The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus","volume":"25","author":"Dawson","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0960-894X(00)00453-4","article-title":"N1-(Benzenesulfonyl)tryptamines as novel 5-HT6 antagonists","volume":"10","author":"Tsai","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2017.20373","article-title":"Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease three randomized clinical trials","volume":"319","author":"Alireza","year":"2018","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e12136","DOI":"10.1002\/trc2.12136","article-title":"Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer\u2019s disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET)","volume":"7","author":"Lang","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1358\/dnp.2010.23.8.1500435","article-title":"The rise and fall of dimebon","volume":"23","author":"Bezprozvanny","year":"2010","journal-title":"Drug News Perspect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13195-018-0368-9","article-title":"A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer\u2019s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil","volume":"10","author":"Fullerton","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40261-018-0618-4","article-title":"Safety, tolerability and pharmacokinetics of the serotonin 5-HT6 receptor antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects","volume":"38","author":"Nirogi","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nirogi, R., Jayarajan, P., Shinde, A., Mohammed, A.R., Grandhi, V.R., Benade, V., Goyal, V.K., Abraham, R., Jasti, V., and Cummings, J. (2023). Progress in investigational agents targeting serotonin-6 receptors for the treatment of brain disorders. Biomolecules, 13.","DOI":"10.3390\/biom13020309"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1021\/acschemneuro.4c00873","article-title":"Procognitive potential of neuroprotective triazine 5-HT6 receptor antagonists tested on chronic activity in vivo in rats: Computer-aided insight into the role of chalcogen-differences on the pharmacological profile","volume":"16","author":"Garbo","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.1021\/jm200466r","article-title":"N\u2032-(Arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT6R) antagonists with unique structural features","volume":"54","author":"Venhorst","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"41293","DOI":"10.1038\/srep41293","article-title":"A new serotonin 5-HT6 receptor antagonist with procognitive activity\u2014Importance of a halogen bond interaction to stabilize the binding","volume":"7","author":"Medina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kraft, F.B., Hanl, M., Feller, F., Sch\u00e4ker-H\u00fcbner, L., and Hansen, F.K. (2023). Photocaged histone deacetylase inhibitors as prodrugs in targeted cancer therapy. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030356"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","article-title":"High throughput artificial membrane permeability assay for blood-brain barrier","volume":"38","author":"Di","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1007\/s12035-018-0881-7","article-title":"The Small GTPase RAC1\/CED-10 is essential in maintaining dopaminergic neuron function and survival against \u03b1-synuclein-induced toxicity","volume":"55","author":"Kim","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102572","DOI":"10.1016\/j.pneurobio.2024.102572","article-title":"Caenorhabditis elegans RAC1\/ced-10 mutants as a new animal model to study very early stages of Parkinson\u2019s disease","volume":"234","author":"Guha","year":"2024","journal-title":"Prog. Neurobiol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lee, A.L., Ung, H.M., Sands, L.P., and Kikis, E.A. (2017). A new Caenorhabditis elegans model of human huntingtin 513 aggregation and toxicity in body wall muscles. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173644"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0014-4886(91)90142-Y","article-title":"Postsynaptic Localization of 5HT1D receptor binning sites in human caudate","volume":"113","author":"Peroutka","year":"1991","journal-title":"Exp. Neurobiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"E56","DOI":"10.1073\/pnas.1415195112","article-title":"HDAC inhibition imparts beneficial transgenerational effects in Huntington\u2019s disease mice via altered DNA and histone methylation","volume":"112","author":"Jia","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9368","DOI":"10.1073\/pnas.92.20.9368","article-title":"Expression of human \u03b2-amyloid peptide in transgenic Caenorhabditis elegans","volume":"92","author":"Link","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1077209","article-title":"Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism","volume":"299","author":"Bonifati","year":"2003","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.freeradbiomed.2017.04.364","article-title":"Identification of potential therapeutic compounds for Parkinson\u2019s disease using Drosophila and human cell models","volume":"108","author":"Sanz","year":"2017","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.gene.2005.06.040","article-title":"Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction","volume":"361","author":"Park","year":"2005","journal-title":"Gene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/17460441.2019.1569624","article-title":"An assessment of the translational relevance of Drosophila in drug discovery","volume":"14","author":"Papanikolopoulou","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1021\/acs.jmedchem.0c00442","article-title":"Design of hydrazide-bearing HDACIs based on panobinostat and their p53 and FLT3-ITD dependency in antileukemia activity","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1021\/acsmedchemlett.1c00702","article-title":"Determination of slow-binding HDAC inhibitor potency and subclass selectivity","volume":"13","author":"Olsen","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/ja993663t","article-title":"Prediction of properties from simulations: Free energies of solvation in hexadecane, octanol, and water","volume":"122","author":"Duffy","year":"2000","journal-title":"J. Am. Chem. Soc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0960-894X(00)00172-4","article-title":"Prediction of drug solubility from Monte Carlo simulations","volume":"10","author":"Jorgensen","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/jcc.21287","article-title":"CHARMM: The biomolecular simulation program","volume":"30","author":"Brooks","year":"2009","journal-title":"J. Comp. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:23:35Z","timestamp":1790000615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27073135"],"URL":"https:\/\/doi.org\/10.3390\/ijms27073135","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}